Cantor Fitzgerald Reiterates Overweight on Aurinia Pharmaceuticals, Maintains $10 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Olivia Brayer has reiterated an Overweight rating on Aurinia Pharmaceuticals (NASDAQ:AUPH) and maintained a $10 price target.
September 16, 2024 | 3:22 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated an Overweight rating for Aurinia Pharmaceuticals, maintaining a $10 price target, indicating confidence in the stock's potential.
The reiteration of an Overweight rating and maintenance of a $10 price target by a reputable analyst suggests positive sentiment and potential upside for AUPH, likely boosting investor confidence and short-term stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100